Evaluating HSCT Refusal Trends Among Patients With Multiple Myeloma

Chakra Chaulagain, MD, director of the multiple myeloma and amyloidosis program at Cleveland Clinic Florida, discusses the context of an analysis which assessed autologous hematopoietic stem cell transplantation (HSCT) refusal rates among patients with multiple myeloma.

According to Chaulagain, autologous HSCT is the standard-of-care for patients with multiple myeloma. This method of treatment has continuously shown to improve survival, including in regard to overall and progression-free survival. Still, patients can decline HSCT as part of their treatment.

In an analysis of 43,653 patients with multiple myeloma recommended for HSCT from 2004 to 2020 who were identified via the NCDB, investigators aimed to understand the patterns and factors behind refusal of HSCT among patients with multiple myeloma.

Transcription:

0:09 | There is minimal data on real-world findings about refusal of a standard-of-care, for example, stem cell transplantation in [patients with] multiple myeloma, so we wanted to explore some ideas about what are the factors that are contributing to the refusal of transplant, which is the current standard-of-care. It is known to improve both progression-free and overall survival based on randomized clinical trials, but there is very limited real-world data around this subject. So we decided to investigate the NCBD database.

0:51 | This is a retrospective analysis of a very large number of [patients with] multiple myeloma that were treated by a commission of cancer accredited cancer centers throughout the United States. There are at least 1500 of these types of cancer centers, and they report to this NCBD, where they have all of this data collected. NCBD captures about 70% of all cancer cases in the United States. We decided to get those data and analyze them just for multiple myeloma with the purpose of finding what are the variables and clinical factors that are responsible for refusal of autologous stem cell transplantation in myeloma patients.

REFERENCE:

Chaulagain CP, Saba L, Sarna K, et al. Exploring autologous hematopoietic Stem cell transplantation (HSCT) utilization and HSCT refusal trends in multiple myeloma patients: A comprehensive examination of NCDB data from 2004 to 2020. Blood. 2023;142 (Suppl 1): 532. doi:10.1182/blood-2023-182051